Top Markets
#1 GEKKO GEKKO +50.71%
#2 Helium Helium +45.05%
#3 TENDIES TENDIES +44.18%
#4 ADO Protocol ADO Protocol +39.08%
#5 Pons Pons +36.21%
#6 Prom Prom +32.22%
#7 o1.exchange o1.exchange +21.80%
#8 StonkBroker StonkBroker +21.46%
#9 Collector Crypt Collector Crypt +20.52%
#10 Nillion Nillion +19.37%
Coin of the day
GEKKO GEKKO
Settings
Language
ENGLISH
Currency
USD
Theme
Orum Therapeutics, Inc. Orum Therapeutics, Inc.

Orum Therapeutics, Inc.

475830
Rank in Stocks #9664
Orum Therapeutics, Inc. is a biopharmaceutical company dedicated to the... Orum Therapeutics, Inc. is a biopharmaceutical company dedicated to the discovery and development of novel therapeutic solutions for both cancer and immune system conditions. The firm specializes in creating degrader-antibody conjugates, an innovative class of drugs that merges traditional antibody-drug conjugate (ADC) technology with targeted protein degradation. Their flagship product candidate, ORM-1153, functions as a GSPT1 protein degrader, specifically engineered to address hematologic malignancies. Orum Therapeutics was established in 2016 and operates out of Daejeon, South Korea.
Share Price
$45.64
Last synced: 2026-08-28
Market Cap
$969.02M
Change (1 day)
-1.20%
Change (1 year)
146.66%
Country
KR
Trade Orum Therapeutics, Inc. (475830)

Category

Healthcare
P/E ratio for Orum Therapeutics, Inc. (475830)
P/E ratio as of 2026 TTM: 0
According to Orum Therapeutics, Inc. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Orum Therapeutics, Inc. from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 32.46 -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -7.93 -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.